Nghĩa của từ aleukemic myelosis bằng Tiếng Việt

Hư tủy không tăng bạch cầu

Đặt câu có từ "aleukemic myelosis"

1. Megakaryocytes from a case of aleukemic megakaryocytic myelosis were examined by electron microscope.

2. Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor

3. Further examinations led to the diagnosis of pernicious anemia and funicular myelosis.

4. To study chronic megakaryocytic-granulocytic myelosis, bone marrow biopsies from 5 patients were obtained.

5. Report of three cases of acute myelosis with the presence of two erythrocyte populations.

6. Our first week back, and I'm look at neuropathy, coagulopathy, myelosis, internal hemorrhaging, renal failure.

7. In particular, the present invention relates to pharmaceuticals containing the said peptides for accelerating osteosis, myelosis and haematogenesis.

8. The LDH-agent is not identical with the myelosis virus, or with other leukemia viruses of the mouse.

9. Plasma from the myelosis rats has no effect in the tissue culture on the P32- uptake of normal bone marrow.

10. The summary in the aforementioned final opinion reads: “Death from anemia due to aleukemic lymphadenosis and prevention of proper medical treatment.”

11. In several series of experiments there were induced: myelosis (34%), myeloblastic leukemia (34%), myelosarcomatosis (11%), reticulosarcomatosis (16%), and lymphatic leukemia (5%).

12. The marrow of rats with a myelosis shows in vitro a decreased rate of uptake of P32 of about 43.2% (±10.3%).

13. All patients demonstrated at the beginning of leukemia aleukemic courses, normal or slightly decreased platelet counts, small tumor masses, and were free of severe infections.

14. Whether or not these differences observed between malignant lymphomas with lymphocytosis (CLL) and those without lymphocytosis (aleukemic CLL, LSA) are characteristic, remains to be studied.

15. A report has been presented concerning the electromicroscopical observation of a necrocyte (necrobiotic destructive cell) occurring in the circulating blood of a patient with myelosis.

16. In acute leucosis and chronic myelosis, the naphthol-AS-esterase reaction occurring in mature neutrophilic granulocytes is significantly lower than in the normal granulocytic cells.

17. A Ph1-negative case did not display leukocytosis and was aleukemic until shortly before a final blast crisis. Granulocytic alkaline phosphatase was in this case always 0.

18. A method of judging leukemia, pre-leukemia or an aleukemic malignant blood disease characterized by comprising quantifying stem cell growth factor (SCGF); a method of discriminating leukemia from pre-leukemia or an aleukemic malignant blood disease; a method of discriminating aplastic anemia from myelodysplastic syndrome; a method of judging delayed take in hematopoietic stem cells after transplantation of the hematopoietic stem cells; and a method of judging graft versus host disease.

19. This is the first case of a megakaryoblastic myelosis, diagnosed in its early phase by bone marrow biopsy, with clinical follow up study and confirmation by autopsy findings.

20. 2 cases, one of polyneuropathy and one of funicular myelosis, in which myelography was performed, are reported. After the insertion of the contrast medium an increase of eosinophil leucocytes was observed.

21. In a girl 10 years of age with selective vitamin B12 malabsorption associated with proteinuria and residual symptoms of funicular myelosis an extensive study of the intestinal and nephrologic functions was done.

22. These cases of CMPD break down into the main groups as follows: CML 23.2 %, megakaryocytic myelosis consistent with agnogenic myeloid metaplasia 22.3 %, essential thrombocythemia 22.1 %, and polycythemia vera 20.4 %; 12.0 % of cases were unclassifiable.

23. If they occur in aleukemic patients incorrect diagnoses may result. Differential diagnostic considerations are being discussed by presenting the case of a 58-year-old man who experienced spinal cord compression by an isolated epidural mass lesion.

24. The invention also discloses the uses of the polypeptide in methods for treating various diseases, such as malignant atypical myelosis syndrome, chronic leukemia, other tumour, nervous system illness, blood malignant illness, development disorder, HIV infection, etc.

25. The present peptides are broadly used to prepare pharmaceuticals for accelerating osteosis, myelosis and haematogenesis, for being assistant for tumor radical therapy, for treating anemia and aplastic anemia, for fatigue resistance, for treating radiation illness and other hemopathies.